December 05, 2013
1 min read

Treatment protocols for VEGF inhibitors in DME await results of major trials

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

VIENNA — VEGF inhibitors are now first-line therapy for center-involved diabetic macular edema with reduced vision, and treatment protocols are rapidly evolving. However, data regarding many aspects of initiation, cessation and restarting of therapy remain unknown, a speaker said at the Advanced Retinal Therapy meeting here.

The Diabetic Retinopathy Clinical Research Network ( protocol trial demonstrated that Lucentis (ranibizumab, Novartis/Genentech) with deferred or prompt focal/grid laser resulted in superior visual acuity outcomes compared with laser alone, Lloyd A. Aiello, MD, said. Over 3 years, more than half of the eyes did not require any focal/grid laser.

Eylea (aflibercept, Regeneron/Bayer HealthCare) was also tested more recently in association with laser and demonstrated similarly better results compared with laser alone. Protocol T is currently comparing aflibercept, ranibizumab and Avastin (bevacizumab, Roche/Genentech). Results are expected within the next 15 months.

Consensus should be reached on treatment protocols following the results of these studies. Meanwhile, Aiello suggested a simplified re-treatment and follow-up algorithm, beginning with an initial series of injections 1 month apart and assessment 1 month later.

“Determine if DME is improving. If it is, re-inject and see the patient again in 1 month,” he said. “If the edema is no longer improving, then you can skip the injection and ask the patient to return for re-evaluation in 1 month. Determine at that time if the edema is worsening or recurring. If it is, re-inject and restart with monthly re-evaluation once again. If it is not worsening or recurring, double the follow-up interval up to 4 months and then re-evaluate for worsening or recurring.”

Disclosure: Aiello is a consultant to Genentech, Novartis and Regeneron.